$MTNB
Matinas BioPharma Holdings, Inc.

2024 Q2 Form 10-Q Financial Statement

#000149315224018417 Filed on May 09, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q1
Revenue $1.096M
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.468M $2.456M $2.712M
YoY Change -5.08% -9.44% -1.17%
% of Gross Profit
Research & Development $3.371M $3.446M $3.970M
YoY Change -5.28% -13.2% -20.25%
% of Gross Profit
Depreciation & Amortization $92.00K $94.00K $93.00K
YoY Change -6.12% 1.08% 23.34%
% of Gross Profit
Operating Expenses $3.371M $3.446M $3.970M
YoY Change -5.28% -13.2% -48.59%
Operating Profit -$5.839M -$5.902M -$5.586M
YoY Change -5.2% 5.66% -27.66%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $120.0K $78.00K $73.00K
YoY Change 21.21% 6.85% 638.12%
Pretax Income -$5.719M -$5.824M -$5.513M
YoY Change -5.63% 5.64% -7.78%
Income Tax
% Of Pretax Income
Net Earnings -$5.719M -$5.824M -$5.513M
YoY Change -5.63% 5.64% -7.78%
Net Earnings / Revenue -503.01%
Basic Earnings Per Share -$0.02 -$0.03 -$0.03
Diluted Earnings Per Share -$0.02 -$0.03 -$0.03
COMMON SHARES
Basic Shares Outstanding 250.8M shares 217.5M shares 217.3M shares
Diluted Shares Outstanding 249.4M shares 217.4M shares 217.3M shares

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $14.31M $8.110M $24.86M
YoY Change -36.42% -67.37% -43.34%
Cash & Equivalents $4.216M $1.071M $5.739M
Short-Term Investments $10.10M $7.039M $19.12M
Other Short-Term Assets $972.0K $2.179M $3.349M
YoY Change -34.63% -34.94% 168.11%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $15.29M $10.29M $28.21M
YoY Change -36.31% -63.52% -37.49%
LONG-TERM ASSETS
Property, Plant & Equipment $1.739M $1.829M $1.998M
YoY Change -17.31% -8.46% -67.31%
Goodwill $1.336M $1.336M $1.336M
YoY Change 0.0% 0.0%
Intangibles $3.017M $3.017M $3.017M
YoY Change 0.0% 0.0%
Long-Term Investments
YoY Change
Other Assets $200.0K $200.0K $200.0K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $9.080M $9.321M $10.06M
YoY Change -9.43% -7.31% -5.72%
TOTAL ASSETS
Total Short-Term Assets $15.29M $10.29M $28.21M
Total Long-Term Assets $9.080M $9.321M $10.06M
Total Assets $24.37M $19.61M $38.26M
YoY Change -28.39% -48.75% -31.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $238.0K $473.0K $516.0K
YoY Change -60.6% -8.33% -61.83%
Accrued Expenses $1.442M $839.0K $791.0K
YoY Change 5.1% 6.07% -53.4%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $5.000K $5.000K $4.000K
YoY Change 0.0% 25.0% -76.65%
Total Short-Term Liabilities $2.392M $1.998M $1.896M
YoY Change -7.61% 5.38% -49.69%
LONG-TERM LIABILITIES
Long-Term Debt $15.00K $16.00K $21.00K
YoY Change -25.0% -23.81%
Other Long-Term Liabilities $2.514M $2.697M $3.379M
YoY Change -21.95% -20.18% -15.39%
Total Long-Term Liabilities $2.870M $3.054M $3.741M
YoY Change -19.88% -18.36% -6.32%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.392M $1.998M $1.896M
Total Long-Term Liabilities $2.870M $3.054M $3.741M
Total Liabilities $5.262M $5.052M $5.637M
YoY Change -14.73% -10.38% -30.43%
SHAREHOLDERS EQUITY
Retained Earnings -$187.1M -$181.4M -$158.1M
YoY Change 13.95% 14.7%
Common Stock $25.00K $22.00K $22.00K
YoY Change 13.64% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $19.10M $14.56M $32.63M
YoY Change
Total Liabilities & Shareholders Equity $24.37M $19.61M $38.26M
YoY Change -28.39% -48.75% -31.41%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q1
OPERATING ACTIVITIES
Net Income -$5.719M -$5.824M -$5.513M
YoY Change -5.63% 5.64% -7.78%
Depreciation, Depletion And Amortization $92.00K $94.00K $93.00K
YoY Change -6.12% 1.08% 23.34%
Cash From Operating Activities -$3.106M -$5.769M -$4.087M
YoY Change 41.63% 41.15% -14.06%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$2.938M $2.000M $3.000M
YoY Change -145.91% -33.33% -14.42%
Cash From Investing Activities -$2.938M $2.000M $3.000M
YoY Change -147.4% -33.33% 1.31%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.189M $53.00K -$4.000K
YoY Change -919000.0% -1425.0% -104.3%
NET CHANGE
Cash From Operating Activities -3.106M -$5.769M -$4.087M
Cash From Investing Activities -2.938M $2.000M $3.000M
Cash From Financing Activities 9.189M $53.00K -$4.000K
Net Change In Cash 3.145M -$3.716M -$1.091M
YoY Change -21.45% 240.6% -35.89%
FREE CASH FLOW
Cash From Operating Activities -$3.106M -$5.769M -$4.087M
Capital Expenditures
Free Cash Flow -$4.087M
YoY Change -2.95%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
CY2023Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
usd
CY2024Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
usd
CY2024Q1 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
usd
CY2024Q1 MTNB Finance Lease Liability Payments Due After Year Four
FinanceLeaseLiabilityPaymentsDueAfterYearFour
usd
CY2023Q4 us-gaap Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
usd
CY2023Q4 us-gaap Finance Lease Liability Payments Due After Year Five
FinanceLeaseLiabilityPaymentsDueAfterYearFive
usd
CY2023Q4 us-gaap Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
usd
CY2023Q4 us-gaap Finance Lease Liability Payments Due After Year Five
FinanceLeaseLiabilityPaymentsDueAfterYearFive
usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
shares
CY2024Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
shares
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1071000 usd
CY2024Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
7039000 usd
CY2024Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
50000 usd
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2129000 usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
10289000 usd
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1829000 usd
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2919000 usd
CY2024Q1 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
20000 usd
CY2024Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3017000 usd
CY2024Q1 us-gaap Goodwill
Goodwill
1336000 usd
CY2024Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
200000 usd
CY2024Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
9321000 usd
CY2024Q1 us-gaap Assets
Assets
19610000 usd
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
473000 usd
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
839000 usd
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
681000 usd
CY2024Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
5000 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1998000 usd
CY2024Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
341000 usd
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2697000 usd
CY2024Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
16000 usd
CY2024Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3054000 usd
CY2024Q1 us-gaap Liabilities
Liabilities
5052000 usd
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
217482830 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
217482830 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
217264526 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
217264526 shares
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
22000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
195018000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-175573000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-221000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
19246000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25104000 usd
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1096000 usd
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3446000 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3970000 usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2456000 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2712000 usd
CY2024Q1 us-gaap Costs And Expenses
CostsAndExpenses
5902000 usd
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
6682000 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5902000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5586000 usd
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
78000 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
73000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-5824000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5513000 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
217358085 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
217358085 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
217264526 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
217264526 shares
CY2024Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
87000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
229000 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
87000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
229000 usd
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5737000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5284000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
19246000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
995000 usd
CY2024Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2000 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
54000 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
87000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-5824000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
14558000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
36637000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
36637000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1272000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
229000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5513000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
32625000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
32625000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-5824000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5513000 usd
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
94000 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
93000 usd
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
995000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1272000 usd
CY2024Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
145000 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
132000 usd
CY2024Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
1000 usd
CY2023Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
4000 usd
CY2024Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
18000 usd
CY2023Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
44000 usd
CY2024Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-154000 usd
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-132000 usd
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
393000 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2420000 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-41000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-102000 usd
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-610000 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2305000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5769000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4087000 usd
CY2024Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
2000000 usd
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
3000000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
2000000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3000000 usd
CY2024Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
54000 usd
CY2024Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
1000 usd
CY2023Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
4000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
53000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-4000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3716000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1091000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5037000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7080000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1321000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5989000 usd
CY2024Q1 MTNB Unrealized Loss On Marketable Securities
UnrealizedLossOnMarketableSecurities
87000 usd
CY2023Q1 MTNB Unrealized Loss On Marketable Securities
UnrealizedLossOnMarketableSecurities
229000 usd
CY2024Q1 us-gaap Nature Of Operations
NatureOfOperations
<p id="xdx_800_eus-gaap--NatureOfOperations_zn6ysMSjrXie" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #000000"><b>Note 1 – <span id="xdx_820_zsaM3O4Fx8Oi">Description of Business</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #000000"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #000000">Matinas BioPharma Holdings Inc. (“Holdings”) is a Delaware corporation formed in 2013. Holdings is the parent company of Matinas BioPharma, Inc. (“BioPharma”), and Matinas BioPharma Nanotechnologies, Inc. (“Nanotechnologies,” formerly known as Aquarius Biotechnologies, Inc.), its operating subsidiaries (“Nanotechnologies”, and together with “Holdings” and “BioPharma”, “the Company”). The Company is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #000000"> </span></p>
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-181397000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-5824000 usd
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1071000 usd
CY2024Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
7039000 usd
CY2024Q1 us-gaap Restricted Cash
RestrictedCash
250000 usd
CY2024Q1 us-gaap Restricted Cash
RestrictedCash
250000 usd
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
250000 usd
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1071000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4787000 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5739000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6830000 usd
CY2024Q1 us-gaap Restricted Cash
RestrictedCash
250000 usd
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
250000 usd
CY2023Q1 us-gaap Restricted Cash
RestrictedCash
250000 usd
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
250000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1321000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5037000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5989000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7080000 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
87000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
229000 usd
CY2024Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
134000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
221000 usd
CY2024Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
7173000 usd
CY2024Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
134000 usd
CY2024Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
7039000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
9190000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
221000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
8969000 usd
CY2024Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
7039000 usd
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
8969000 usd
CY2024Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3618000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3618000 usd
CY2024Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3618000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3618000 usd
CY2024Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1789000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1695000 usd
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1829000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1923000 usd
CY2024Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
94000 usd
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
93000 usd
CY2024Q1 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
501000 usd
CY2023Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
1176000 usd
CY2024Q1 MTNB Accrued General And Administrative Expenses Current
AccruedGeneralAndAdministrativeExpensesCurrent
223000 usd
CY2023Q4 MTNB Accrued General And Administrative Expenses Current
AccruedGeneralAndAdministrativeExpensesCurrent
196000 usd
CY2024Q1 MTNB Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
115000 usd
CY2023Q4 MTNB Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
75000 usd
CY2024Q1 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
839000 usd
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
1447000 usd
CY2024Q1 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
Some leases include purchase, termination or extension options for one or more years.
CY2024Q1 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P12M
CY2024Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
226000 usd
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
226000 usd
CY2024Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
145000 usd
CY2024Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
145000 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
132000 usd
CY2024Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1000 usd
CY2023Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1000 usd
CY2024Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
1000 usd
CY2023Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
4000 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
721000 usd
CY2024Q1 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
5000 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
998000 usd
CY2024Q1 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
7000 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1040000 usd
CY2024Q1 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
7000 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
944000 usd
CY2024Q1 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
7000 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
273000 usd
CY2024Q1 MTNB Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
138000 usd
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
273000 usd
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
138000 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
4114000 usd
CY2024Q1 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
26000 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
736000 usd
CY2024Q1 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
5000 usd
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
3378000 usd
CY2024Q1 us-gaap Finance Lease Liability
FinanceLeaseLiability
21000 usd
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y1M6D
CY2024Q1 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P3Y8M12D
CY2024Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.092 pure
CY2024Q1 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.116 pure
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
956000 usd
CY2023Q4 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
7000 usd
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
998000 usd
CY2023Q4 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
7000 usd
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1040000 usd
CY2023Q4 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
7000 usd
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
944000 usd
CY2023Q4 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
7000 usd
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
273000 usd
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
138000 usd
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
4349000 usd
CY2023Q4 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
28000 usd
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
816000 usd
CY2023Q4 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
5000 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
3533000 usd
CY2023Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
23000 usd
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y3M18D
CY2023Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P3Y10M24D
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.092 pure
CY2023Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.116 pure
CY2024Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
218304 shares
CY2023Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
0 shares
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
46031560 shares
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
34915699 shares
CY2023Q4 MTNB Net Unrealized Gains Losses On Availableforsale Securities
NetUnrealizedGainsLossesOnAvailableforsaleSecurities
-221000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-221000 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
87000 usd
CY2024Q1 MTNB Accumulated Other Comprehensive Lossgain Net Unrealized Loss On Securities Availableforsale
AccumulatedOtherComprehensiveLossgainNetUnrealizedLossOnSecuritiesAvailableforsale
87000 usd
CY2024Q1 MTNB Net Unrealized Gains Losses On Availableforsale Securities
NetUnrealizedGainsLossesOnAvailableforsaleSecurities
-134000 usd
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-134000 usd
CY2022Q4 MTNB Net Unrealized Gains Losses On Availableforsale Securities
NetUnrealizedGainsLossesOnAvailableforsaleSecurities
-824000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-824000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
229000 usd
CY2023Q1 MTNB Accumulated Other Comprehensive Lossgain Net Unrealized Loss On Securities Availableforsale
AccumulatedOtherComprehensiveLossgainNetUnrealizedLossOnSecuritiesAvailableforsale
229000 usd
CY2023Q1 MTNB Net Unrealized Gains Losses On Availableforsale Securities
NetUnrealizedGainsLossesOnAvailableforsaleSecurities
-595000 usd
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-595000 usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
The term of the Plan was for 10 years
CY2024Q1 MTNB Increased Shares Of Common Stock Outstanding
IncreasedSharesOfCommonStockOutstanding
8690581 shares
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
0.04 pure
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
995000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1272000 usd
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
6840000 usd
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y4M24D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
46707934 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
676374 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
46031560 shares

Files In Submission

Name View Source Status
0001493152-24-018417-index-headers.html Edgar Link pending
0001493152-24-018417-index.html Edgar Link pending
0001493152-24-018417.txt Edgar Link pending
0001493152-24-018417-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex4-6.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
form10-q_001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
mtnb-20240331.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
mtnb-20240331_def.xml Edgar Link unprocessable
mtnb-20240331_lab.xml Edgar Link unprocessable
mtnb-20240331_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
mtnb-20240331_cal.xml Edgar Link unprocessable